Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 2 diabetes who have never received any hypoglycemic treatment；~2. Fasting plasma glucose (FPG) between 7.0 mmol/l (126 mg/dl) and 16.7 mmol/l (300 mg/dl);~3. glycosylated hemoglobin A1C≥8.5%;~4. Aged between 20 and 70 years 5） body mass index (BMI) 22-35 kg/m2.~Exclusion Criteria:~1. Type 1 diabetes or special type of diabetes;~2. Acute complications of diabetes (including DKA, HHS and lactic acidosis)~3. Serious microvascular complications: proliferative stage of retinopathy; urine AER \>300 mg/g or urine protein positive, quantification \>0.5 g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;~4. Severe macrovascular complications: acute cerebrovascular accident, acute coronary syndrome, vascular intervention for peripheral arterial disease or amputation requiring hospitalization within 12 months prior to enrollment;~5. Persistently increased blood pressure \>180/110 mmHg;~6. Blood creatinine clearance less than 50 ml/min, alanine aminotransferase ≥2.5×upper limit of normal, total bilirubin ≥1.5×upper limit of normal;~7. Hemoglobin \<100 g/L or need regular blood transfusion;~8. Use of drugs that may influence blood glucose within 12 weeks;~9. Systemic infection or serious concomitant disease; patients with malignancy or chronic diarrhea;~10. Uncontrolled endocrine gland dysfunction;~11. Patients with mental or communication disorders;~12. Chronic cardiac insufficiency, heart function class III and above;~13. Pregnant women, lactating women and women of child bearing age who are not willing to take contraception during the study;~14. Subjects who don't cooperate, cannot be followed up or have difficulty in completing the study considered by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin plus metformin (Type: ACTIVE_COMPARATOR): CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
- Linagliptin (Type: ACTIVE_COMPARATOR): CSII followed by Linagliptin 5mg Qd for 48 weeks
- Metformin (Type: ACTIVE_COMPARATOR): CSII followed by Metformin 0.5 bid for 48 weeks
- Lifestyle alone (Type: ACTIVE_COMPARATOR): No OHA is given after CSII

Based on this trial design, predict the completion outcome and termination type (if applicable).